Wall Street Zen Upgrades Inventiva (NASDAQ:IVA) to “Hold”

Inventiva (NASDAQ:IVA) was upgraded by analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Other analysts have also issued reports about the stock. HC Wainwright lifted their price target on shares of Inventiva from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Thursday, October 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Inventiva in a research report on Tuesday, September 30th. Piper Sandler started coverage on Inventiva in a report on Wednesday, August 27th. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Guggenheim raised their price target on Inventiva from $9.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, September 2nd. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $16.14.

Inventiva Price Performance

Shares of NASDAQ:IVA opened at $4.85 on Friday. The business has a 50-day simple moving average of $5.28 and a two-hundred day simple moving average of $4.02. Inventiva has a fifty-two week low of $2.11 and a fifty-two week high of $6.55.

Institutional Investors Weigh In On Inventiva

A hedge fund recently raised its stake in Inventiva stock. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) by 54.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,558 shares of the company’s stock after purchasing an additional 5,843 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Inventiva were worth $50,000 at the end of the most recent quarter. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.